Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Chemo Enzymatic Synthesis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN110343734B details a novel amidase method for L-glufosinate. Offers 100% theoretical yield and reduced environmental burden for agrochemical manufacturing.
Novel chemo-enzymatic route enhances yield and purity for 2'-deoxyuridine. Offers significant cost reduction in API manufacturing and supply chain stability.
Patent CN118638174A reveals a plant-based UDCA synthesis route. Achieve 99.91% purity with reduced viral risk and scalable enzymatic steps for reliable supply.
Patent CN119119158A reveals a novel plant-derived route for ursodeoxycholic acid. Achieve high purity and cost reduction in API manufacturing with scalable bio-hybrid synthesis.
Novel chemo-enzymatic route for diabetes drug intermediate offers high purity and scalable manufacturing solutions for global pharmaceutical supply chains efficiently.
Novel chemo-enzymatic route for Eluxadoline intermediate. High yield, scalable, cost-effective pharmaceutical intermediates manufacturing for global supply chains.
Novel chemo-enzymatic route for pseudouridine offers high purity and scalable production for mRNA vaccine manufacturers seeking reliable supply.
Patent CN114196715A details a novel chemo-enzymatic method for pseudouridine using engineered glycosidase mutants, offering high conversion and simplified purification for mRNA vaccine supply chains.
Patent CN114592027A reveals a novel two-step method for Tauroursodeoxycholic Acid production, offering significant cost reduction in API manufacturing and high-purity outcomes.
Patent CN110643670A details a high-yield chemoenzymatic route for D-glutamine production, offering significant cost reduction in pharmaceutical manufacturing and scalable supply solutions.
Patent CN111233949A details a novel one-pot three-enzyme method for GM3 synthesis, offering high stereoselectivity and cost reduction for pharmaceutical intermediate manufacturing.
Patent CN102899367B details a hybrid bio-chemical synthesis for high-purity Tenofovir. This method offers significant cost reduction and scalable manufacturing for API intermediates.
Patent CN106701882A details a novel chemo-enzymatic route for UDCA production offering high purity and scalable manufacturing capabilities for global pharmaceutical supply chains.